Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
156.24 -1.23 (-0.78%) 15:21 ET [NYSE]
156.22 x 167 156.25 x 44
Realtime by (Cboe BZX)
156.22 x 167 156.25 x 44
Realtime 157.48 +0.01 (+0.01%) 09:29 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
155.49
Day High
158.23
Open 157.96
Previous Close 157.47 157.47
Volume 3,319,413 3,319,413
Avg Vol 11,377,510 11,377,510
Stochastic %K 66.50% 66.50%
Weighted Alpha +5.01 +5.01
5-Day Change +4.48 (+2.95%) +4.48 (+2.95%)
52-Week Range 140.68 - 169.99 140.68 - 169.99
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 379,478,752
  • Shares Outstanding, K 2,409,848
  • Annual Sales, $ 88,821 M
  • Annual Income, $ 14,066 M
  • EBIT $ 14,023 M
  • EBITDA $ 21,362 M
  • 60-Month Beta 0.49
  • Price/Sales 4.18
  • Price/Cash Flow 11.73
  • Price/Book 5.18

Options Overview Details

View History
  • Implied Volatility 21.71% ( +2.40%)
  • Historical Volatility 31.57%
  • IV Percentile 95%
  • IV Rank 40.58%
  • IV High 35.15% on 04/08/25
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.61
  • Today's Volume 22,516
  • Volume Avg (30-Day) 55,231
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 452,218
  • Open Int (30-Day) 465,256

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 2.66
  • Number of Estimates 7
  • High Estimate 2.76
  • Low Estimate 2.56
  • Prior Year 2.82
  • Growth Rate Est. (year over year) -5.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.50 +10.39%
on 04/09/25
Period Open: 163.63
166.63 -6.26%
on 03/31/25
-7.43 (-4.54%)
since 03/21/25
3-Month
141.50 +10.39%
on 04/09/25
Period Open: 148.15
169.99 -8.11%
on 03/04/25
+8.06 (+5.44%)
since 01/21/25
52-Week
140.68 +11.04%
on 01/10/25
Period Open: 147.91
169.99 -8.11%
on 03/04/25
+8.29 (+5.61%)
since 04/19/24

Most Recent Stories

More News
This Dividend King Just Raised Its Payout for a 63rd Consecutive Year

Although there has been a lot of turmoil in the markets in recent weeks, many top dividend stocks are ...

JNJ : 156.17 (-0.83%)
2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government

In 2011, following the difficulty caused by the Great Recession, S&P Global Ratings (formerly Standard & Poor's) downgraded the long-term credit outlook of the United States from its highest designation...

MSFT : 357.50 (-2.80%)
JNJ : 156.17 (-0.83%)
3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now

Dividend stocks can be fantastic investments. The best ones pay an attractive and growing stream of dividend income while also delivering healthy stock price appreciation over the long term. That combination...

INVH : 33.12 (-1.49%)
$SPX : 5,115.75 (-3.16%)
JNJ : 156.17 (-0.83%)
NEE : 63.79 (-3.80%)
Where Will Eli Lilly Be in 5 Years?

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY) . In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer , and Merck...

NVO : 58.20 (+0.21%)
MRK : 77.33 (-0.86%)
JNJ : 156.17 (-0.83%)
LLY : 811.32 (-3.41%)
PFE : 21.94 (-0.90%)
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

J&J JNJ began the earnings season for the drug and biotech sector this week. Pfizer PFE announced the discontinuation of its danuglipron weight loss pill program. The European Commission granted marketing...

JNJ : 156.17 (-0.83%)
RHHBY : 38.6600 (-0.62%)
PFE : 21.94 (-0.90%)
SNY : 50.74 (-0.31%)
Here's How You Should Play JNJ Stock After Q1 Earnings Beat

Earlier this week, J&J JNJ began the first-quarter earnings season for the drug and biotech sector with better-than-expected results.J&J’s first-quarter adjusted earnings were $2.77 per share, which...

JNJ : 156.17 (-0.83%)
KVUE : 22.25 (-4.87%)
TEVA : 13.27 (-2.78%)
AMGN : 271.92 (-1.94%)
4 Reasons Johnson & Johnson Could Be the Perfect Stock to Own in Today's Turbulent Market

It's less than four months into the year, and many investors are already exhausted. The wild stock market swings fueled by the Trump administration's tariffs are to blame.

$SPX : 5,115.75 (-3.16%)
JNJ : 156.17 (-0.83%)
This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row

Johnson & Johnson (NYSE: JNJ) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%. That extended its dividend...

JNJ : 156.17 (-0.83%)
KVUE : 22.25 (-4.87%)
Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ

Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room...

JNJ : 156.17 (-0.83%)
ACI : 22.12 (+1.89%)
KR : 71.93 (+1.00%)
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios

JNJ : 156.17 (-0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 165.17
2nd Resistance Point 162.30
1st Resistance Point 159.89
Last Price 156.17
1st Support Level 154.61
2nd Support Level 151.74
3rd Support Level 149.33

See More

52-Week High 169.99
Fibonacci 61.8% 158.79
Last Price 156.17
Fibonacci 50% 155.33
Fibonacci 38.2% 151.88
52-Week Low 140.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro